Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.54 |
| ▸ | XIAP | P98170 | 17/20 | 0.51 |
| ▸ | NPY1R | P25929 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1998088 | 0.87 | METAP1 (0.50) | METAP1XIAPNPY1R | |
| SCHEMBL12569069 | 0.87 | METAP1 (0.50) | METAP1XIAPNPY1R | |
| SCHEMBL12569070 | 0.87 | METAP1 (0.50) | METAP1XIAPNPY1R | |
| SCHEMBL1998951 | 0.87 | METAP1 (0.49) | METAP1XIAP | |
| SCHEMBL2233896 | 0.87 | METAP1 (0.49) | METAP1XIAPNPY1R | |
| SCHEMBL12345878 | 0.87 | METAP1 (0.49) | METAP1XIAPNPY1R | |
| SCHEMBL1998952 | 0.87 | METAP1 (0.49) | METAP1XIAP | |
| SCHEMBL2233891 | 0.87 | METAP1 (0.49) | METAP1XIAPNPY1R | |
| SCHEMBL4484884 | 0.87 | METAP1 (0.49) | METAP1XIAP | |
| SCHEMBL4484881 | 0.87 | METAP1 (0.49) | METAP1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099152-A1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZAZEPINES, THE PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI-AVENTIS (FR) | 2009-04-16 | — | — | US | claimed |
| US-7994162-B2 | 2-alkoxy-3,4,5-trihydroxy-alkylamide-benzazepines, the preparation and use thereof, and compositions containing the same | SANOFI-AVENTIS (FR) | 2011-08-09 | — | — | US | disclosed |
| US-7994162-B2 | 2-alkoxy-3,4,5-trihydroxy-alkylamide-benzazepines, the preparation and use thereof, and compositions containing the same | SANOFI-AVENTIS (FR) | 2011-08-09 | — | — | US | disclosed |
| US-7994162-B2 | 2-alkoxy-3,4,5-trihydroxy-alkylamide-benzazepines, the preparation and use thereof, and compositions containing the same | SANOFI-AVENTIS (FR) | 2011-08-09 | — | — | US | disclosed |
| US-20090099152-A1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZAZEPINES, THE PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI-AVENTIS (FR) | 2009-04-16 | — | — | US | disclosed |
| US-20090099152-A1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZAZEPINES, THE PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI-AVENTIS (FR) | 2009-04-16 | — | — | US | disclosed |
| US-20090099152-A1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZAZEPINES, THE PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI-AVENTIS (FR) | 2009-04-16 | — | — | US | disclosed |
| WO-2007135293-A2 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZAZEPINES, THE PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI AVENTIS (FR) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099152-A1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZAZEPINES, THE PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | GABRA5, GABRA2, GABRA3 | METAP1 4009/4885XIAP 4788/4885NPY1R 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.